- Mineralys Therapeutics recently reported a first-quarter 2026 net loss of US$39.34 million and announced that it will present Phase 3 Launch-HTN data for its lead candidate lorundrostat in uncontrolled hypertension and chronic kidney disease at the European Meeting on Hypertension and Cardiovascular Protection on May 30, 2026.
- This upcoming disclosure of late-stage efficacy and safety results for lorundrostat in a complex patient group could meaningfully influence how investors assess Mineralys’ cardiorenal pipeline potential.
- We’ll now examine how the upcoming Phase 3 Launch-HTN lorundrostat data presentation might reshape Mineralys Therapeutics’ investment narrative and risk profile.
Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.
Mineralys Therapeutics Investment Narrative Recap
To own Mineralys Therapeutics, you need to believe lorundrostat can carve out a meaningful role in hard‑to‑treat hypertension and related cardiorenal disease, and that the company can eventually scale from a single‑asset, loss‑making biotech into a sustainable commercial business. The upcoming Phase 3 Launch‑HTN CKD data are a key near term catalyst, while continued net losses, including the Q1 2026 net loss of US$39.34 million, keep financing and execution risk front and center.
The most relevant recent update is Mineralys’ plan to present Launch‑HTN Phase 3 data in uncontrolled hypertension with chronic kidney disease at ESH 2026. This disclosure directly intersects with the existing NDA for lorundrostat in hypertension and the push to extend into comorbid conditions. How compelling these CKD data look on efficacy and safety could influence how investors weigh the potential for label expansion against the ongoing cash burn and competitive class pressures.
Yet while lorundrostat’s CKD data may broaden the opportunity, investors should also be aware that...
Read the full narrative on Mineralys Therapeutics (it's free!)
Mineralys Therapeutics' narrative projects $215.7 million revenue and $23.5 million earnings by 2029. This requires revenue to grow from zero to $215.7 million over the period and a $194.9 million earnings increase from -$171.4 million today.
Uncover how Mineralys Therapeutics' forecasts yield a $50.88 fair value, a 93% upside to its current price.
Exploring Other Perspectives
Before this update, the most optimistic analysts were modeling revenue of about US$388 million and earnings near US$49 million by 2029, which is far more bullish than the consensus view that focuses on regulatory and single asset risk; depending on how the new Phase 3 data land, you may find your own expectations shifting somewhere between these very different stories.
Explore 4 other fair value estimates on Mineralys Therapeutics - why the stock might be worth just $48.50!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Mineralys Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Mineralys Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mineralys Therapeutics' overall financial health at a glance.
No Opportunity In Mineralys Therapeutics?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
- AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com